Bromodeoxyuridine (BrdU)

A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.

Also Known As:

Networked: 2796 relevant articles (43 outcomes, 294 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ono, Koji: 28 articles (01/2014 - 03/2002)
2.	Suzuki, Minoru: 24 articles (01/2014 - 01/2003)
3.	Kinashi, Yuko: 20 articles (10/2010 - 12/2002)
4.	Chopp, Michael: 15 articles (11/2014 - 01/2002)
5.	Nagata, Kenji: 15 articles (01/2008 - 01/2003)
6.	Masunaga, Shin-Ichiro: 14 articles (01/2014 - 03/2002)
7.	Liu, Yong: 13 articles (11/2015 - 10/2005)
8.	Ono, K: 13 articles (03/2012 - 02/2000)
9.	Masunaga, Shin-ichiro: 13 articles (10/2010 - 12/2002)
10.	Sakurai, Yoshinori: 12 articles (01/2014 - 12/2002)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2008 - "These results suggest that BrdU may have an important role as an adjunctive therapeutic for a wide variety of cancers based on new insights into its effect as a negative regulator of cell cycle progression." 11/01/1994 - "Bromodeoxyuridine indices over 10 per mile had a positive predictive value of 79 per cent for cancers extending beyond the prostatic capsule and may prove particularly helpful for evaluating patients with grade 7 cancer. " 01/01/2012 - "In tumor-bearing mice, we found that Helios(+) Treg were relatively over-represented in the tumor-mass, and BrdU studies showed that, in vivo, Helios(+) Treg proliferated more than Helios(-) Treg. " 11/01/2008 - "Immunohistochemistry was performed to identify BrdU-positive cells to study tumor cell proliferation. " 07/15/2006 - "Compound 3 exhibited more than 300-fold selectivity for CDK4 over CDK1, 2, 5, 7, and 9. Subsequent improvements in aqueous solubility afforded compound 4, which is available for further in vivo studies and this compound inhibited pRb phosphorylation and BrdU incorporation in tumor models."
2.	Seizures (Seizure) 09/01/2002 - "Amygdaloid kindling in partial seizure (PS) was effective in proliferation of NSC detected with BrdU-labeling in subventricular zone (SVZ), but not in dentate gyrus (DG). " 02/01/2008 - "In the present study, quantitative analysis of BrdU labeling revealed a significant increase in the proliferation rate of neuronal progenitor cells after KA-induced seizures in the KD-fed mice. " 02/15/2004 - "Rats were injected with bromodeoxyuridine to label proliferating cells in the dentate gyrus after single/multiple electroconvulsive seizures in a dose-response study and at various time points after single electroconvulsive seizures in a time-course study. " 08/01/2015 - "Results found that, 2R, 4R-APDC could significantly inhibit the behavioral seizure and block the seizure-induced increase of BrdU-positive cells in dentate gyrus, especially in hilus. " 11/01/2014 - "Here, we have addressed this issue by analyzing immunohistochemically: (1) the brain levels of total and phosphorylated mTOR in young (before seizures) and adult WAG/Rij rats; (2) the proliferation of hippocampal neuronal stem/progenitor cells assessed by BrdU analysis at different ages. "
3.	Inflammation 05/01/2008 - "This study investigated the frequency of BrdU or SPION uptake by AM using the Boyden chamber model of inflammation. " 12/01/2015 - "In CUEDC2 KO mice, the NF-κB and STAT3 signaling pathways were increasingly activated in different stages of progression of the colonic inflammation, and the percentage of proliferating cells as indicated by Ki67, CyclinD1, and BrdU in the inflammatory tissues was significantly increased. " 05/01/2015 - "These results indicate that long-term exposure to BrdU inhibits cell proliferation and induces low-grade inflammation in the lungs of mice. " 05/01/2015 - "Repeated exposure to 5-bromo-2'-deoxyuridine causes decreased proliferation and low-grade inflammation in the lungs of mice." 01/01/2013 - "During the chronic phase (3 months post IR), we found that LPS-induced inflammation at the time of IR aggravated the IR-induced injury in both male and female mice, as judged by reduced bromodeoxyuridine incorporation and neurogenesis (doublecortin-positive cells) in the hippocampus. "
4.	Stroke (Strokes) 06/01/2009 - "In addition, postischemic survival of endogenous doublecortin (Dcx)-positive NPC was improved within the lesioned striatum of TAT-Hsp70-treated animals for up to 4 weeks after stroke without changing overall cell proliferation of BrdU(+) cells. " 10/01/2015 - "n-3 PUFAs also robustly improved revascularization and angiogenesis and boosted the survival of NeuN/BrdU labeled newborn neurons up to 35days after stroke injury. " 01/01/2015 - "After stroke, BRDU incorporation into monocytes in the bone marrow increased. " 01/01/2015 - "Aging also inhibited migration of neuroblasts (DCX(+) cells), as indicated by an accumulation of neuroblasts at migratory zones 14 days after injury; consistently, aged mice presented a smaller number of differentiated interneurons (NeuN(+)/BrdU(+) and GAD67(+) cells) in the peri-infarct cortical area 14 days after stroke. " 11/01/2014 - "Consistently, TLR4(+/+) mice showed an increased number of interneurons (NeuN(+)/BrdU(+)/GAD67(+) cells) in peri-infarct cortex 14-28 d after stroke. "
5.	Glioma (Gliomas) 08/01/1990 - "We have shown in a Phase I study that IA BUdR radiosensitization is safe, tolerable, may lead to improved survival, and appears to be an efficacious primary treatment of malignant gliomas." 09/01/1989 - "Since 1965, BAR therapy (BrdU-antimetabolite-radiation therapy), in which BrdU was administered intraarterially as a radiosensitizer, has been applied to patients with malignant gliomas and the improvement in survival rate within two years has been reported. " 01/16/2000 - "Both Ki-67 expression and BrdU incorporation are also useful methods in the study of gliomas. " 01/01/1999 - "A correlative study of gliomas using in vivo bromodeoxyuridine labeling index and computer-aided malignancy grading." 01/01/2015 - "Glioma cell proliferation was evaluated by CCK8 and BrdU incorporation assay. "

Related Drugs and Biologics

1.	Bromodeoxyuridine (BrdU)
2.	Thymidine
3.	DNA (Deoxyribonucleic Acid)
4.	nestin (nestin protein)
5.	Fluorouracil (Carac)
6.	Bleomycin (Blenoxane)
7.	Tamoxifen
8.	Antigens
9.	Histones (Histone)
10.	Tretinoin (Retinoic Acid)

Related Therapies and Procedures

1.	Radiotherapy
2.	Intra-Arterial Infusions
3.	Injections
4.	Catheters
5.	Drug Therapy (Chemotherapy)